The FGF Metabolic Axis
Chapter 1 Growth Factors Reviews
Fibroblast growth factors,old kids on the new block
Pharmacological application of growth factors: basic and clinical
Cytokines and diabetes research
Small molecule inhibition of fibroblast growth factor receptors in cancer
Research advances in tissue engineering materials for sustained release of growth factors
Minireview: roles of fibroblast growth factors 19 and 21 in metabolic regulation and chronic diseases
Physiological and pharmacological roles of FGF21 in cardiovascular diseases
Fibroblast growth factor 21 deficiency exacerbates chronic alcohol-induced hepatic steatosis and injury
Delivery of growth factor-based therapeutics in vascular diseases: challenges and strategies
Fibroblast growth factor 10 in pancreas development and pancreatic cancer
Chapter 2 Injury Repair and Regeneration
TAT-mediated acidic fibroblast growth factor delivery to the dermis improves wound healing of deep skin tissue in rat
Regulation of autophagy and ubiquitinated protein accumulation by bFGF promotes functional recovery and neural protectzion in a
rat model of spinal cord injury
The anti-scar effects of basic fibroblast growth factor on the wound repair in vitro and in vivo
Exogenous basic fibroblast growth factor inhibits ER Stress-induced apoptosis and improves recovery from spinal cord injury
FGF10 protects against renalischemia/reperfusion injury by regulating autophagy and infiammatory signaling
Reduction of cellular stress is essential for Fibroblast growth factor 1 treatment for diabetic nephropathy
Chapter 3 Endocrinology and Metabolism
Fibroblast growth factor 21 (FGF21) therapy attenuates left ventricular dysfunction and metabolic disturbance by improving
FGF21 sensitivity,cardiac mitochondrial redox homoeostasis and structural changes in pre-diabeticrats
NMR-based metabolomics reveal a recovery from metabolic changes in the striatum of 6-OHDA-induced rats treated with basic
fibroblast growth factor
FGF21 mediates alcohol-induced adipose tissuelipolysis by activation of systemic release of catecholamine inmice
Fibroblast growth factor 21 deletion aggravates diabetes-induced pathogenic changes in the aorta in type 1 diabetic mice
Additive protection by LDR and FGF21 treatment against diabetic nephropathy in type 2 diabetes model
FGF21 deletion exacerbates diabetic cardiomyopathy by aggravating cardiac lipid accumulation
Fibroblast growth factor 21 prevents atherosclerosis by suppression of hepatic sterol regulatory element-binding protein-2 and
induction of adiponectininmice
Attenuation of hyperlipidemia and diabetes-induced early-stage apoptosis and late-stage renal dysfunction via administration
offibroblast growth factor-21 is associated with suppression of renal infiammation
The prevention of diabetic cardiomyopathy by non-mitogenic acidic fibroblast growth factor is probably mediated by the
suppression of oxidative stress and damage
Pancreatic fibroblast growth factor 21 protects against type 2 diabetes in mice by promoting insulin expression and secretion in a
PI3K/Akt signaling-dependent manner
……
Chapter 4 Structure and Modification
Chapter 5 Signaling Pathway and Pharmacology
Chapter 6 Pharmaceutics and New Material
Chapter 7 Bioreactor and Engineering
Chapter 8 FGFR and Inhibitors
Chapter 9 Others